Trial Profile
An Open-label, Cohort Study of Grazoprevir/Elbasvir Combination Therapy for Patients With Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 Dec 2021 Results published in the Antimicrobial Agents and Chemotherapy
- 14 Mar 2021 Status changed from recruiting to discontinued due to COV-19 pandemic.
- 29 Aug 2020 Results (n=11; October 2019) assessing efficacy and tolerability of GZR/EBR combination therapy in genotype 1b HCV-infected liver or kidney transplant recipients, presented at The International Liver Congress 2020